Clinical trials
Solid Tumor Cancer clinical trials
Below are recruiting solid tumor cancer clinical trials, each written for real people, not researchers. We’re tracking 1,461 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03465592RecruitingPhase 1/Phase 2
Nivolumab after mismatched bone marrow transplant for sarcoma
This trial studies nivolumab (an immune treatment) in people with sarcoma who already had a partially mismatched bone marrow transplant. It may help the new immune system recognize and attack cancer, and researchers will also watch closely for side effects like GVHD (immune reaction after transplant) and autoimmune problems.
St. Petersburg, FloridaAges 1–40 - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Santa Rosa, CaliforniaAges 18–80 - NCT03594422RecruitingPhase 1
Testing an oral drug for GIST or other solid tumors
This Phase 1 trial tests HQP1351, a new oral cancer drug, in people with advanced GIST or other solid tumors that have not responded to prior treatment. It’s mainly designed to check safety and how the drug works in the body, which may lead to better options for tumors that have progressed.
Guangzhou, GuangdongAges 12 years+ - NCT03658785RecruitingPhase 1/Phase 2
Immunotherapy for advanced solid tumors using patient tumor cells
This trial tests an immunotherapy made from your own tumor-fighting immune cells (TIL). It may help people with advanced solid cancers that cannot be cured with surgery or radiation.
Wuhan, HubeiAges 18–70 - NCT03686124RecruitingPhase 1/Phase 2
Tested immune therapy for certain HLA-A2 positive solid tumors
This trial studies an immune-based cancer treatment (IMA203/IMA203CD8) either alone or with nivolumab in people whose solid tumors have come back or will not respond to standard care. It may help by training the immune system to recognize and attack tumor cells that match the trial’s test requirements.
Stanford, CaliforniaAges 18 years+ - NCT03740256RecruitingPhase 1
HER2-targeted oncolytic virus plus custom immune cells for solid cancers
This Phase 1 study tests a treatment plan that combines a virus designed to attack cancer with your own custom immune cells that target HER2. It aims to shrink advanced HER2-positive solid tumors (and make future options safer/more effective).
Houston, TexasAges 18 years+ - NCT03778814RecruitingPhase 1
Personalized T-cell therapy for advanced lung or solid tumors
This Phase 1 study tests a lab-made immune cell treatment made from your own blood cells (T cells) to fight advanced lung cancer or other solid tumors. You may be eligible if your tumor can be biopsied and the lab can successfully prepare T cells that strongly recognize and attack your cancer.
Guanzhou, GuangdongAges 18–75 - NCT03823144Recruiting
Imaging small live tumor details during surgery
This study uses a special camera to look at solid tumors from inside the body during an operation. It tests whether “live” tumor imaging (using a medicine called fluorescein) can be safely performed in people with certain solid cancers.
Jacksonville, FloridaAges 18 years+ - NCT03866525RecruitingPhase 1/Phase 2
Test an oncolytic virus treatment for solid tumors
This early-stage study tests a virus therapy designed to attack solid tumors that cannot be removed by surgery or have returned/spread. It may help shrink tumors and control cancer in people whose standard treatments are no longer working.
Beijing, Beijing MunicipalityAges 18–75 - NCT03917043RecruitingPhase 1
Testing a new targeted drug for ALK or ROS1 lung cancers
This Phase 1 trial tests APG-2449, a new drug, in people with advanced solid tumors—especially certain lung cancers that have ALK or ROS1 gene fusions. Because it’s an early safety-and-dose study, it may help learn how well the drug works and what doses are safe.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03943004RecruitingPhase 1
Study drug DFP-14927 for advanced solid tumors
This Phase 1 trial tests DFP-14927, a new study drug, in adults with advanced solid tumors that have not responded to standard treatments. It’s designed to see if the drug is safe and to learn how it works in people with limited treatment options.
Los Angeles, CaliforniaAges 18 years+ - NCT03947385RecruitingPhase 1/Phase 2
First drug test for metastatic uveal melanoma with specific gene changes
This Phase 1/2 trial studies IDE196 in adults with metastatic uveal melanoma that has certain gene mutations or fusions. It’s mainly testing safety and correct dosing, and may help shrink tumors in patients matched to the tumor’s genetic changes.
Los Angeles, CaliforniaAges 18 years+ - NCT07583654RecruitingPhase 1
Testing a New mRNA Cancer Treatment for Advanced Solid Tumors
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
Chengdu, SichuanAges 18–70 - NCT07702162RecruitingPhase 1
Testing PA5 in advanced solid tumors
This trial tests a new drug called PA5 for people with advanced solid tumors that no longer respond to standard treatments. The goal is to see if PA5 is safe and how well it works against these cancers.
Fuzhou, FujianAges 18 years+ - NCT04015609Recruiting
Spanish therapy sessions for Latino people with advanced cancer
This study tests a psychotherapy (talking/support) intervention designed for Latino/Hispanic adults with stage III or IV solid tumor cancer. It uses Spanish-only questionnaires and interviews, and may help by addressing emotional distress during advanced cancer care.
New York, New YorkAges 18 years+ - NCT04094610RecruitingPhase 1/Phase 2
Repotrectinib for kids with certain cancer gene changes
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
Los Angeles, CaliforniaAges Up to 25 years - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75 - NCT04145622RecruitingPhase 1/Phase 2
Ifinatamab deruxtecan for advanced hard-to-treat solid cancers
This early-stage trial tests an investigational antibody-drug medicine (ifinatamab deruxtecan) in people with advanced solid tumors. It aims to see whether it can shrink tumors or help control cancer, and to learn about side effects and the best way to use it.
Los Angeles, CaliforniaAges 18 years+ - NCT04151342Recruiting
Study of Canadian adults with cancer rare DNA changes
This real-world study follows adults in Canada who have cancer that was tested and found to have rare molecular (DNA/protein) changes. It helps researchers understand how these rare findings show up and how care happens in everyday practice.
Calgary, AlbertaAges 18 years+ - NCT04165772RecruitingPhase 2
Dostarlimab for locally advanced mismatch-repair deficient solid tumors
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
Hartford, ConnecticutAges 18 years+ - NCT04196257RecruitingPhase 1
Early-dose trial of BP1001-A for advanced or recurrent solid tumors
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
Silver Spring, MarylandAges 18 years+ - NCT04243720Recruiting
Study of immune resistance after immunotherapy
This trial studies why some solid cancers stop responding to immune-based drugs (like anti–PD-1/PD-L1) and what can be done next. You may be eligible if your cancer has progressed after immunotherapy and you can safely undergo a tumor needle biopsy.
Toronto, OntarioAges 18 years+ - NCT04354064Recruiting
Blood DNA test to see early treatment response in solid tumors
This study looks at circulating tumor DNA, which is tiny bits of DNA found in blood, to help assess how solid tumors are responding early. It uses blood samples from healthy adults who are willing to donate.
St Louis, MissouriAges 18 years+ - NCT04370587RecruitingPhase 1/Phase 2
Injecting a cancer medicine into tumors plus pembrolizumab
This Phase 1/2 study tests a medicine injected directly into a tumor, alone or with pembrolizumab (an immune-therapy drug given through a vein). It is for people with advanced or metastatic solid cancers that have grown despite standard treatments, aiming to improve tumor control.
Gilbert, ArizonaAges 18 years+
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor cancer?
- Yes. Clin2 currently lists 1,461 recruiting solid tumor cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.